What is the appropriate management for a 70‑year‑old woman with a 1.8 cm right‑sided ductal carcinoma in situ with microinvasion that is estrogen‑receptor positive, progesterone‑receptor negative, and HER2 positive?

Management of ER+/PR-/HER2+ DCIS with Microinvasion in a 70-Year-Old Woman

This 70-year-old woman with a 1.8 cm ER+/PR-/HER2+ ductal carcinoma in situ with microinvasion should undergo breast-conserving surgery with sentinel lymph node biopsy, followed by adjuvant radiation therapy, endocrine therapy with an aromatase inhibitor, and 1 year of trastuzumab-based HER2-targeted therapy.

Surgical Management

Primary Tumor Resection

• Breast-conserving surgery (lumpectomy) is appropriate given the tumor size of 1.8 cm 1
• Ensure negative surgical margins with adequate excision 2
• Obtain post-operative mammogram to document complete removal of any associated calcifications 2

Axillary Management

Sentinel lymph node biopsy (SLNB) should be performed despite the microinvasive component 2, 3. Key considerations:

• Microinvasion carries a risk of occult invasive disease that may harbor nodal metastases 4, 5
• HER2-positive status increases the likelihood of upstaging to invasive carcinoma 6, 7
• SLNB at the time of initial surgery avoids the need for a second procedure if invasion is found on final pathology 2
• Recent evidence shows that even biopsy-diagnosed DCIS can present with nodal metastasis when occult invasion exists 5

Critical pitfall: While some advocate omitting SLNB in low-risk DCIS 3, 7, the HER2-positive status in this case increases upstaging risk and warrants axillary staging 6.

Radiation Therapy

Adjuvant radiation therapy to the breast is strongly recommended after breast-conserving surgery 1, 8:

• All DCIS subgroups benefit from radiation after lumpectomy 2, 8
• HER2-positive DCIS shows substantial benefit from radiotherapy in reducing local recurrence 6
• Radiation should be administered after completion of chemotherapy if given 1
• Can be given concurrently with trastuzumab and endocrine therapy 1, 9

Systemic Therapy

HER2-Targeted Therapy (Priority Treatment)

One year of adjuvant trastuzumab is indicated 1, 9:

• Even microinvasive HER2+ disease warrants consideration of trastuzumab 1, 9, 4
• The NCCN guidelines support trastuzumab for HER2-positive tumors ≥0.6 cm (T1b) 9
• A case report demonstrated favorable outcomes with trastuzumab in DCIS-MI with HER2 overexpression 4
• Preferred regimen: Paclitaxel plus trastuzumab for lower-risk, small HER2-positive tumors, which showed 10-year invasive disease-free survival of 91.3% 9

Administration details:

• Trastuzumab should be given for 1 year total 1
• May use weekly or every-3-week schedule 1
• Can be administered concurrently with radiation and endocrine therapy 1, 9
• Do not give concurrent with anthracyclines due to cardiac toxicity 1
• Requires cardiac monitoring throughout treatment 1
• FDA-approved biosimilars are acceptable substitutes 9

Endocrine Therapy

Adjuvant endocrine therapy is indicated for ER-positive disease 1, 10, 11:

• Aromatase inhibitor is preferred over tamoxifen in this postmenopausal 70-year-old woman 1, 11
• Should be given sequentially after chemotherapy completion 1
• Can be given concurrently with trastuzumab and radiation 1, 9
• Duration: typically 5 years 11, 8

Important consideration: The PR-negative status suggests potential endocrine resistance and reinforces the importance of HER2-targeted therapy 10, 12. The ER+/PR- phenotype carries independent prognostic implications 12.

Chemotherapy Considerations

Chemotherapy should be considered given the HER2-positive status and microinvasion 1, 9:

• Retrospective evidence suggests anthracycline-based regimens may be superior in HER2-positive tumors 1
• However, for this lower-risk presentation (microinvasion, 1.8 cm), paclitaxel plus trastuzumab is the preferred less-intensive option 9
• If more aggressive chemotherapy is chosen, options include AC followed by paclitaxel plus trastuzumab 1

Treatment Sequence

The optimal sequence for this patient:

1. Surgery first: Lumpectomy with SLNB
2. Systemic therapy: Paclitaxel plus trastuzumab (if chemotherapy given)
3. Radiation therapy: After chemotherapy completion
4. Continue trastuzumab: Complete 1 year total, concurrent with radiation
5. Endocrine therapy: Aromatase inhibitor, started after chemotherapy, concurrent with trastuzumab

Age-Specific Considerations

At age 70 with good performance status 13:

• Surgery is safe and feasible despite age 3
• Radiation therapy remains beneficial and should not be omitted based on age alone 13
• Trastuzumab has a favorable safety profile with low cardiac toxicity risk (0.5% heart failure) 9
• Monitor bone health if using aromatase inhibitor 1

Key Clinical Pitfalls to Avoid

1. Do not omit SLNB based solely on "DCIS" diagnosis when HER2-positive, as upstaging risk is significant 6, 7
2. Do not withhold trastuzumab based on microinvasion alone—HER2-positive microinvasive disease can exhibit aggressive behavior 4, 5
3. Do not use tamoxifen preferentially in this postmenopausal woman—aromatase inhibitors are superior 1, 11
4. Do not give anthracyclines concurrent with trastuzumab due to cardiac toxicity 1
5. Do not interpret residual calcifications post-treatment as viable tumor—they may represent necrotic debris 5